Efficacité du tofacitinib sur l'enthésite chez les patients atteints de rhumatisme psoriasique actif : Analyse des données regroupées de deux études de phase 3
Arthritis Res Ther. 2023 22;25(1):153 doi: 10.1186/s13075-023-03108-5
Post-hoc analysis of two tofacitinib phase three studies concludes that tofacitinib treatment resulted in improvements in enthesitis in patients with PsA, regardless of baseline location or severity.
Enthesitis, reported in up to 50% of patients with PsA, is associated with greater disease activity and radiographic peripheral and axial joint damage, as well as worse functional status, greater fatigue and pain, and reduced work productivity, compared with patients without enthesitis.
In this post-hoc analysis, Mease, et al. assess tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and PROs, in patients with PsA.
Keywords:
